2. Metabolic Enzyme/Protease Epigenetics Cell Cycle/DNA Damage Cytoskeleton Apoptosis Autophagy Protein Tyrosine Kinase/RTK NF-κB PI3K/Akt/mTOR
  3. NAMPT Sirtuin Microtubule/Tubulin Apoptosis Autophagy PDGFR NF-κB AMPK
  4. Myricanol

Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Myricanol

Myricanol 構造式

CAS 番号 : 33606-81-4

容量 価格（税別） 在庫状況 数量
1 mg $680 在庫あり
5 mg $1700 在庫あり
10 mg $2900 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Myricanol 関連抗体

Top Publications Citing Use of Products

Sirtuin アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7 SIRT4

PDGFR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
PDGFR PDGFRβ PDGFRα

NF-κB アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

AMPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation[1][2][3][4][5][6][7][8].

IC50 & Target[2][6][7]

SIRT1

 

NF-κB

 

AMPK

 

PDGFRβ

 

Cellular Effect
Cell Line Type Value Description References
RAW264.7 IC50
7.5 3
Compound: 153
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
[PMID: 33422907]
RAW264.7 IC50
7.5 3
Compound: 153
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
[PMID: 33422907]
RAW264.7 IC50
7.5 3
Compound: 153
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
[PMID: 33422907]
体外実験

Myricanol (0.01-150 μM ,1-72 h) effectively reduces tau levels in HEK293T cells with IC50 of approximately 18.56 μM and mouse acute ex vivo brain tissues (100 and 150 μM) through activation of autophagy[1].
Myricanol (0-10 μM, 24 h) significantly reverses the reduction in mitochondrial content and functional impairment induced by Dexamethasone (DEX) (HY-14648), and promotes autophagy and inhibits apoptosis to protect C2C12 myotubes through activating sirtuin 1[2].
Myricanol (1.25-5 μmol/L, 24 h) decreases lipid accumulation and enhances mitochondrial function in Palmitic acid (PA) (HY-N0830)-treated C2C12 myotubes and protects C2C12 myotubes against insulin resistance, and increases irisin production and secretion in C2C12 myotubes, which in turn induces the browning of adipocytes[3].
Myricanol (5-20 μM) inhibits renal fibrosis by invigorated TFAM and ameliorate the interaction between ZNRF1 and LCN2 and aggravates ferroptosis in TGF-β1-induced HK2 cells[4].
MY (2.5-10 μM) protects C2C12 myotubes against oxidative damage treated by tert-butyl hydroperoxide (TBHP) and improves mitochondrial biogenesis and function through targeting PRDX5[5].
Myricanol (3-30 μM, 24.5 h) inhibits the proliferation and migration of vascular smooth muscle cells induced by platelet derived growth factor-BB by inhibiting the activation of platelet-derived growth factor receptor pathway and NF-κB p65 translocation[6].
Myricanol (5-40 μM, 24 h) targets Nampt in C2C12 cells, which involved in the insulin sensitizing effect[7].
Myricanol (1.56-50 μg/mL, 48 h-10 d) inhibits A549 cells proliferation (IC50 = 4.85 μg/mL) and clonogenic formation and induces apoptosis[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Myricanol 関連抗体

Western Blot Analysis[1]

Cell Line: HEK293T cells
Concentration: 18 μM
Incubation Time: 1, 6, 24, 48, 72 h
Result: Completely be blocked the tau-lowering effect by 3-MA (HY-19312).
Increased the LC3β-II/I ratio.

Western Blot Analysis[2]

Cell Line: C2C12 myotubes stimulated by with DEX
Concentration: 0, 0.25, 5, 10 μM
Incubation Time: 24 h
Result: Restored the expression of myosin heavy chain (MyHC), muscle atrophy F-box protein (atrogin-1), and muscle ring-finger protein 1 (MuRF1).
Dose-dependent upregulated SIRT1 expression.
Restored the phosphorylation of Akt and FoxO3a that is inhibited by DEX.
Increased the expression levels of Cox2, Tom20, UCP3, and PGC-1α.
Reversed DEX-induced increases of total and acetylated FoxO3a levels, which were abolished by co-treatment of EX-527 (HY-15452).
Inhibited expression of apoptosis-associated proteins Bax, cleaved caspase-3 and Increased Bcl-2.

Western Blot Analysis[3]

Cell Line: C2C12 myotubes stimulated by with PA
Concentration: 1.25, 2.5, and 5 μmol/L
Incubation Time: 24 h
Result: Activated the AMPK/ACC signaling pathway and upregulated the expression of PGC-1α.
Activated of the insulin signaling pathway (IRS-1/Akt/GSK-3β).
Promoted the production and secretion of FNDC5/irisin.
Decreased the lipid accumulation in 3T3‐L1 adipocytes in a dose-dependent manner.
Increased the browning markers, PGC‐1α and UCP1, and the mitochondrial marker, COX2, and Suppressed the adipogenic marker, PPARγ, in 3T3‐L1 adipocytes, dose-dependently.

Cell Migration Assay [6]

Cell Line: Primary VSMCs
Concentration: 3, 10 and 30 μM
Incubation Time: Pretreated 30 min and treated with PDGF-BB for 24 h
Result: Partially suppressed the migration at 10 and 30 μM.

Western Blot Analysis[6]

Cell Line: Primary VSMCs
Concentration: 3, 10 and 30 μM
Incubation Time: Pretreated 30 min and treated with PDGF-BB for 24 h
Result: Reduced PCNA, E2F1 and p-Rb.
Reduced Cyclin D1, Cyclin E1 and recovered p53.
Inhibited MM2 and MM9.
Inhibited PDGFRβ pathway and MAPK pathway.
Significantly inhibited p65 nuclear accumulation.

Cell Proliferation Assay[8]

Cell Line: A549 cells
Concentration: 1.56, 3.125, 6.25, 12.5, 25 and 50 μg/mL
Incubation Time: 48 h
Result: Inhibited cell proliferation in a concentration-dependent manner.

Apoptosis Analysis[8]

Cell Line: A549 cells
Concentration: 5 μg/mL
Incubation Time: 48 h
Result: Increased the apoptosis rate from 4.13% to 34.3%, and the proportion of early apoptosis increased significantly.
Upregulated Caspase-3, Caspase-9, Bax and p21, downregulated Bcl-2.
体内実験

Myricanol (5-50 mg/kg, i.p., once daily for 10 days) prevents Dexamethasone-induced muscle atrophy and weakness in mice by activating SIRT1[2].
Myricanol (0.5-2.5 mg/mL, dissolved in PEG 400 (HY-Y0873A) solution, i.p., once daily for 18 weeks) retards fat mass gain and improves lipid profiles and improves insulin sensitivity in high-fat diet (HFD)-fed mice[3].
Myricanol (0.5-2 mg/mL, i.p., once daily for 1 weeks) efficiently improves renal function and suppresses fibrosis in chronic kidney disease (CKD) mice[4].
Myricanol (10-50 mg/kg, i.p., once daily for 20 days) protects aged mice against muscle wasting through alleviating oxidative damage in mitochondria and identify the direct protein target and its underlying mechanism[5].
Myricanol (5 mg/kg, i.p., once daily for 14 days) significantly diminishes the neointimal hyperplasia induced by carotid artery ligation[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DEX-induced muscle dysfunction established in male C57BL/6 mice (8-10 weeks old)[2]
Dosage: 5 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 10 days
Result: Reduced the loss of muscle mass.
Rescued dexamethasone-induced muscle weakness, indicated by improved grip strength.
Upregulated SIRT1 and PGC-1α, reduced atrogin-1/MuRF1.
Animal Model: HFD model established in male C57BL/6 mice (8-10 weeks old)[3]
Dosage: 0.5 and 2.5 mg/mL, dissolved in PEG 400 (HY-Y0873A) solution
Administration: Intraperitoneal injection (i.p.), once daily for 18 weeks
Result: Inhibited weight gain induced by high-fat diet and reduces fat tissue accumulation.
Improved the glucose tolerance and insulin sensitivity of HFD mice (reduce the HOMA-IR index).
Reduced serum triglycerides, total cholesterol and LDL cholesterol, and increased HDL cholesterol).
Increased energy consumption (oxygen consumption).
Reduced lipid deposition in skeletal muscles and improved muscle function (as measured by grip strength test).
Activated the AMPK/PGC-1α signaling pathway in skeletal muscle.
Increased the expression of FNDC5 in skeletal muscle and the serum level of irisin.
Induced the browning of white adipose tissue in the groin region.
Animal Model: CKD model induced by unilateral ureteral obstruction (UUO) established in male C57BL/6 mice (6-8 weeks old)[4]
Dosage: 0.5 and 2 mg/mL along with an equal volume of normal saline
Administration: Intraperitoneal injection (i.p.), once daily for one weeks
Result: Significantly reduced serum creatinine and urea nitrogen levels.
Showed a 40-60% reduction in collagen deposition.
Downregulated fibrosis markers (FN, α-SMA).
Significantly upregulated TFAM and GPX4 expressions and decreased 4-HNE.
Animal Model: Sarcopenia phenotypes model established in 18-month-old male C57BL/6J mice[5]
Dosage: 10 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 10 days
Result: Improved grip strength in aging mice.
Significantly improved Quad, Gast and TA muscle index.
Reduced mitochondrial vacuolization and cristae structure disruption.
Animal Model: Carotid artery wire ligation injury model established in eight-week-old male C57BL/6 mice[6]
Dosage: 5 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 14 days
Result: Showed significantly reduced intima, both the ratio of intima to media (I/M ratio) and intimal area.
Had significantly inhibited Ki67 expression and F4/80 expression.
分子量

358.43

分子式

C21H26O5
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

COC1=C(C=C(CCCC[C@H]2O)C(O)=C1OC)C(C=C(CC2)C=C3)=C3O
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
純度とドキュメンテーション
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Myricanol Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Myricanol33606-81-4NAMPTSirtuinMicrotubule/TubulinApoptosisAutophagyPDGFRNF-κBAMPKNicotinamide phosphoribosyl transferasePBEFVisfatinpre-B cell-enhancing factorPre-B cell colony enhancing factorPlatelet-derived growth factor receptorNuclear factor-κBNuclear factor-kappaBAMP-activated protein kinaseSIRT1DexamethasoneMuscle atrophyPGC-1αAnti-cancer activityCell growth inhibitionInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Myricanol
製品番号:
HY-N3225
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.